Benmelstobart Plus Anlotinib and Chemotherapy Shows Benefit for Patients with Extensive-Stage Small-Cell Lung Cancer

SINGAPORE, Sept. 10, 2023 /PRNewswire-PRWeb/ -- The combination of benmelstobart, anlotinib, and chemotherapy demonstrated significant benefits compared to placebo and chemotherapy in terms of median progression-free survival and overall survival for patients with extensive-stage...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: TRI Source Type: news